Myeloproliferative Neoplasms (MPN) and COVID-19
MPN-COVID
1 other identifier
observational
552
9 countries
44
Brief Summary
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Typical duration for all trials
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2020
CompletedFirst Posted
Study publicly available on registry
May 12, 2020
CompletedStudy Start
First participant enrolled
May 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2022
CompletedSeptember 15, 2025
September 1, 2025
1.8 years
May 11, 2020
September 9, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
pulmonary embolism (PE)
Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
2 and a half months
Secondary Outcomes (10)
fatal or non fatal thrombotic event
2 and a half months
Continuous Positive Airway Pressure (CPAP)
2 and a half months
invasive ventilation
2 and a half months
admission in Intensive Care Unit (ICU)
2 and a half months
death
2 and a half months
- +5 more secondary outcomes
Eligibility Criteria
Patients with Myeloproliferative Neoplasm (Polycythemia Vera, Essential Polycythemia, Myelofibrosis) diagnosed with COVID-19 between 15 February 2020 and 15 February 2022
You may qualify if:
- Age \> 18 years
- Confirmed diagnosed of MPN according to WHO criteria
- Diagnosis of COVID-19 based by the positivity of oropharyngeal swab performed between 15 February 2020 up to 15 February 2022
- Signed informed consent
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (44)
New York-Presbyterian/Weill Cornell Medical Center
New York, New York, 10065, United States
National Specialised Hospital for Active Treatment of Hematological Diseases
Sofia, Bulgaria
University hospital Dubrava-School of Medicine University of Zagreb
Zagreb, Croatia
Hopital Saint-Louis
Paris, France
University Hospital Halle, Department of Hematology/Oncology
Halle, Saale, 06112, Germany
University Medical Center RWTH
Aachen, Germany
University Medicine Greifswald - Hematology, Oncology, Stem Cell Transplantation and Palliative Care
Greifswald, 17475, Germany
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center
Minden, Germany
Ospedale San Gerardo di Monza
Monza, Monza Brianza, 20900, Italy
A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria
Alessandria, 15121, Italy
ASST-Papa Giovanni XXIII
Bergamo, 24127, Italy
Policlinico S.Orsola-Malpighi
Bologna, 40138, Italy
ASST-Spedali Civili
Brescia, 25123, Italy
AOU Ospedale Careggi
Florence, 50134, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
Azienda Ospedaliero Universitaria Maggiore della Carità
Novara, 28100, Italy
IRCCS Policlinico San Matteo
Pavia, 27100, Italy
Policlinico Universitario Fondazione Agostino Gemelli
Roma, 00168, Italy
A.O.U. Città della Salute e della Scienza di Torino
Torino, 10126, Italy
Ospedale Policlinico "G.B. Rossi" Borgo Roma
Verona, 37134, Italy
Ospedale San Bortolo
Vicenza, 36100, Italy
Sobas Wroclaw Medical University ·
Wroclaw, Poland
Hospital Clínic De Barcelona
Barcelona, Barcellona, Spain
Hospital del Mar
Barcelona, Barcellona, Spain
Institut Català d' Oncologia - Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
ICO L'Hospitalet - Hospital Moisès Broggi
Sant Joan Despí, Barcelona, Spain
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, Madrid, Spain
Hospital General de La Palma
Breña Alta, Santa Cruz De Tenerife, Spain
Servicio de Hematología Hospital General Universitario de Albacete
Albacete, Spain
Hospital General de Elche
Alicante, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Burgos
Burgos, Spain
ICO Girona Hospital Josep Trueta Servei d'hematologia
Girona, Spain
FEA Hematología Hospital Universitario de Móstoles
Madrid, Spain
Hospital 12 de octubre
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Gregorio Marañón
Madrid, Spain
Hospital Moncloa
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Clínico Universitario
Valencia, Spain
Guy's and St. Thomas' NHS Foundation Trust.
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Tiziano Barbui, Prof
Fondazione per la Ricerca Ospedale di Bergamo
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2020
First Posted
May 12, 2020
Study Start
May 13, 2020
Primary Completion
February 15, 2022
Study Completion
August 31, 2022
Last Updated
September 15, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
Each participant can visualize its own data on eCRF after the completion patient's electronic data form.